Table 6. Overall effect of the cost-sharing change on the pharmaceutical consumption by comorbidities ^NOTE.

	Low-income pensioners and low-income working population analysis	Middle-income working population and low-income working population analysis
People who have been dispensed medicines of two or more therapeutic groups
During-before the announcement	5.56***(1.12)	0.56 (1.44)
After-during the announcement	-20.37***(0.98)	-1.27 (1.16)
People who have been dispensed medicines of one therapeutic group
During-before the announcement	1.15***(0.35)	0.01 (0.16)
After-during the announcement	2.60*** (0.32)	0.43*** (0.14)

The table contains Difference-in-Difference estimates from linear regression models with robust standard errors. Each cell contains results of the model from different therapeutic groups. All regressions include age and age2, and time dummies. Within each cell, we first report the estimated coefficients; we then report in parentheses robust standard errors. The therapeutic groups are sorted by price-elasticity (at the top the most inelastic, while at the bottom the most elastic).

NOTE: We were not able to exactly know if the individuals of the sample had comorbidities because we did not have information about the specific diseases of each individual. Therefore, we have approached the case of a patient having comorbidities as one who has been dispensed medicines of two or more therapeutic groups. We compared these results with the effect of a patient who has been dispensed medicines from one therapeutic group.

Significance levels

***p < 0.01

**p < 0.05.